1979. Phase III studies on novel oral anticoagulant for stroke prevention in atrial fibrillation a look beyond the excellent results 1988. Contemporary managementof primary immune thrombocytopenia…
2215 Regulators of G protein signaling role in hematopoiesis megakaryopoises and platelet function 2223 The evolution and value of bleeding assesment tools 2230 Anticoagulants in cancer 2242 Reg…
2418 The future of glycoprotein VI as an antiihrombotic target 2428 Von willebrand factor the old the new and the unknown 2438 Air pollution, vascular disease and thrombosis linking clinical data…
327 Response variability to clopidogrel is tailored treatment based on laboratory testing the right solution 337 Exogenous activated protein C inhibits the progression of diabetic nephropathy 34…
985 safety of catheter delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion 992 Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal …
1207. The impact of blood coagulabillity on atherosclerosis and cardiovascular disease 1217. Aspirin twice a day keeps new COX-1 at bay 1220. The recovery of platelet cyclooxygenase activity expl…
1 Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria 11 Isolated distal deep vein thrombosis what we know and what we are doing 20 Reduced cardiovascular m…
167 Novel roles of cAMP/cGMP dependent signaling in platelets 177 Megakarycocytes malignancy and bone marrow vascular 189 Comparison of associations of adherence to a dietary approaches to stop h…
1. VKORC1 molecular target of coumarins 7 Type 1 von willebrand disease 12 In vivo thrombus formation 18 Mechanics of proplatet elaboration 24 Fibrin and fibrinolysis in infection and host defense
1 Fibrinogen concentrate for management of bleeding 6 Fibrinogen concentrate for management of bleeding against indiscriminate use 9 Factor XIII novel strutcural and functional aspects 21 Bewar…